Psilocybin alongside psychological support is safe, tolerable, and deemed acceptable and therapeutically meaningful by female clinical trial participants with anorexia nervosa. drknatzpeck WalterKaye UCSD_EDC
. When queried about the lack of weight change, one treatment responder stated, ‘The irony is that now that I want to recover I can eat intuitively, but that is not enough to support physical recovery’. These findings may suggest that targeted nutritional rehabilitation emblematic of traditional treatment may be a necessary adjunctive treatment even when significant improvements in ED psychopathology are conferred.
Limitations of this study include its small sample size, the lack of a control comparison and the open-label design. Owing to the exploratory nature of this study, we did not conduct a power analysis or correct for multiple comparisons. As a result, these findings are not conclusive and should be interpreted with caution. Additionally, all of the participants were self-referred, which may have resulted in a selection bias.
Strengths of this study included administration of a precise dose of pure synthesized psilocybin and the evaluation of a highly novel treatment modality for a treatment-resistant population. Larger, adequately powered, well-controlled trials with comparator treatments are needed to evaluate the efficacy of psilocybin therapy in a diverse sample of patients with AN.
In conclusion, results from this open-label, single-arm study suggest that psilocybin therapy is safe and tolerable in participants with AN; however, adequately powered, randomized controlled trials are needed to draw any conclusions.This open-label pilot study evaluated the safety, tolerability and preliminary efficacy of psilocybin therapy for participants with AN.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial - Nature MedicineIn the NATION-1907 trial, treatment of patients with resectable esophageal squamous cell carcinoma with the anti-PD-L1 agent adebrelimab was safe and showed preliminary overall survival efficacy, with responders exhibiting an immune-enriched tumor microenvironment phenotype at baseline.
Leer más »
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial - Nature MedicineTrastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also observed in patients with HER2-low or non-expressing tumors, potentially pointing to additional determinants of drug efficacy.
Leer más »
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial - Nature MedicineTreatment of patients with HER2-mutant non-small-cell lung cancer with the pan-HER inhibitor pyrotinib in a phase 2 trial or compassionate use showed a favorable objective response rate, whereas patients treated in parallel by physician’s choice in a real-world study did not.
Leer más »
Psychedelic psilocybin could treat anorexia in some patients, trial suggestsTen patients with anorexia were treated with psilocybin and reported a positive experience, and four experienced remission of their symptoms.
Leer más »
UW begins recruitment for psychedelic cancer therapy studyA psilocybin survey investigates psychedelics affect on anxiety.
Leer más »
Commuter alert: SEPTA will temporarily close Penn Medicine Station; Alter 3 Regional Rail linesBe prepared for the work week. Due to a project started on Saturday, SEPTA's Penn Medicine Station is now closed and its Media/Wawa, Wilmington/Newark, and Airport Lines are impacted by construction.
Leer más »